Fig. 2
From: Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration
PKAN symptoms and functional limitations with increased frequency across the spectrum of PKAN severity (a), Greater frequency in the Highest Severity group (b), or younger age at onset across PKAN severity (c). In panel C, the n values show the actual number of patients reporting age at onset (numerator) and the total number of patients who experienced the problem (denominator) within each severity group. PKAN, pantothenate kinase-associated neurodegeneration